Description: Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Home Page: www.akaritx.com
AKTX Technical Analysis
75/76 Wimpole Street
London,
W1G 9RT
United Kingdom
Phone:
44 20 8004 0270
Officers
| Name | Title |
|---|---|
| Dr. Ray Prudo-Chlebosz M.D. | Exec. Chairman |
| Dr. Torsten Hombeck | Chief Financial Officer |
| Ms. Rachelle Suzanne Jacques | Pres, CEO & Director |
| Ms. Melissa Bradford-Klug | Chief Operating Officer |
| Dr. Miles Nunn | Chief Scientific Officer |
| Dr. John F. Neylan III, M.D. | Exec. VP & Chief Medical Officer |
| Annie Mack | Financial Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4316 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-09-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |